New therapeutic options in uveitis.
Most patients with sight-threatening posterior uveitis eventually end up on systemic medication to control their disease. Although the more aggressive approach to the use of these drugs does offer the patient a better chance of significant visual improvement at least in the short term, this is often associated with severe systemic side-effects in both the young and older patient. Cyclosporin has become a very useful second-line agent as a steroid sparer in those patients who can tolerate it. However, it is not suitable for or effective in everyone and the other currently available drugs are often of limited effectivity or associated with major systemic sequelae. This paper summarises the therapeutic approaches currently being examined to define whether they have a role in the better management of these patients in the future. Particularly exciting is the potential for sustained intraocular drug delivery so that adequate drug levels are achieved inside the eye without the necessity for systemic administration.
Lightman
S
S
Department of Clinical Ophthalmology, Moorfields Eye Hospital, London, UK. s.lightman@ucl.ac.uk
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000941:Antigens / Q000008:administration & dosage; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D007108:Immune Tolerance; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D053685:Laser Therapy; D012160:Retina / Q000276:immunology; D015866:Uveitis, Posterior / Q000188:drug therapy* / Q000628:therapy; D014821:Vitrectomy
D000305:Adrenal Cortex Hormones; D000941:Antigens; D007166:Immunosuppressive Agents